Author

E. Aquilanti

h-index 8 View on Semantic Scholar

We have 2 of 46 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial

We conducted a randomized surgical window-of-opportunity trial (NCT04606316) in recurrent, resectable glioblastoma. Between 2021 and 2024, 71 patients were screened, and 63 were randomized (intention-to-treat [ITT] population), and 58 received study treatment. Patients received pre-surgical immune checkpoint blockade (...

Lu Sun, Lauren Markus, Julio C. Sanchez et al. · Nature Communications · 0 citations

Review Aug 2026

Exploring the landscape of targetable alterations in patients with glioblastoma.

The therapeutic landscape of targeted therapies in glioblastomas is summarized, spanning major target classes including receptor tyrosine kinases, intracellular signalling proteins, cell-cycle dysregulation and synthetic-lethal vulnerabilities and emerging strategies targeting genome integrity and telomeres, epigenetic...

E. Aquilanti, M. Touat, P. French et al. · Nature Reviews Clinical Onco... · 0 citations